I must confess -- I love that this company's ticker symbol is "HOWL". I also am very hopeful that the delivery of its recombinant IL-2 in solid tumor patients (now in clinical trials). . . will mitigate the off-target effects more than occasionally seen in such patients, as a combination therapy with Merck's juggernaut.
In any event, this is a big boost for Dr. Isaacs' thesis, at Werewolf:
. . .“Werewolf Therapeutics is delighted to be partnering with Merck to study the combination of KEYTRUDA and WTX-124, a molecule designed to deliver IL-2 preferentially to the tumor microenvironment and the first of Werewolf’s INDUKINE portfolio to enter the clinic,” said Randi Isaacs, M.D., Chief Medical Officer of Werewolf Therapeutics.
“The clinical benefit of targeting IL-2 as a treatment for cancer has long been established; however, its utility has been limited by challenging toxicities. We believe WTX-124 has the potential to enhance therapeutic options for cancer patients as a monotherapy and when combined with checkpoint inhibitors like KEYTRUDA. . . .”
Onward, and thanks go to our erstwhile long term anonymous commenter for this head's up -- back into the power alley material! Grinning. . . ever grinning -- STEM again, on fleek. . . .
नमस्ते
2 comments:
And a quote from one of my favorite movies...."Werewolf-" "There wolf-" Young Frankenstein.
". . .There, castle. . . ."
"Fancy a. . . r-h-oll, in they-hey...?"
Hilarious -- Peter Boyle, especially.
Namaste. . . .
Post a Comment